Published in Immunology on January 01, 1995
Interleukin-5 modulates interleukin-8 secretion in eosinophilic inflammation. Mediators Inflamm (1998) 0.82
Effects of dexamethasone and cyclosporin A on the accumulation of eosinophils in acute cutaneous inflammation in the guinea-pig. Br J Pharmacol (1996) 0.81
VCAM-1 contributes to rapid eosinophil accumulation induced by the chemoattractants PAF and LTB4: evidence for basal expression of functional VCAM-1 in rat skin. Immunology (1999) 0.78
Effect of soluble P55 tumour-necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions. Br J Pharmacol (1996) 0.75
Simulated bacterial infection disrupts the circadian fluctuation of immune cells in wrinkle-lipped bats (Chaerephon plicatus). PeerJ (2017) 0.75
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 27.85
Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med (1988) 7.12
Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature (1990) 4.21
Biology of the RANTES/SIS cytokine family. Cytokine (1991) 3.97
Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76
The intratracheal administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate. Am J Pathol (1991) 2.30
Cytokine expression by neutrophils and macrophages in vivo: endotoxin induces tumor necrosis factor-alpha, macrophage inflammatory protein-2, interleukin-1 beta, and interleukin-6 but not RANTES or transforming growth factor-beta 1 mRNA expression in acute lung inflammation. Am J Respir Cell Mol Biol (1994) 1.99
Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med (1987) 1.95
Evidence that neutrophil accumulation induced by interleukin-1 requires both local protein biosynthesis and neutrophil CD18 antigen expression in vivo. Br J Pharmacol (1988) 1.90
Domestic endotoxin exposure and clinical severity of asthma. Clin Exp Allergy (1991) 1.90
Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci U S A (1991) 1.67
Inflammatory response to acute inhalation of endotoxin in asthmatic patients. Am Rev Respir Dis (1992) 1.55
The accumulation of 111In-eosinophils induced by inflammatory mediators, in vivo. Immunology (1991) 1.55
Release of tumor necrosis factor by human polymorphonuclear leukocytes. Blood (1990) 1.50
Cachetin/TNF-alpha in septic shock and septic adult respiratory distress syndrome. Am Rev Respir Dis (1988) 1.38
Lung cell reactions after inhalation of bacterial lipopolysaccharides. Eur J Respir Dis (1982) 1.38
Endotoxin-macrophage interaction: post-translational regulation of tumor necrosis factor expression. J Immunol (1989) 1.32
Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha. J Clin Invest (1993) 1.23
Eosinophil accumulation induced by human interleukin-8 in the guinea-pig in vivo. Immunology (1993) 1.23
Asthma. Eosinophils and neutrophils. Br Med Bull (1992) 1.17
Lung reactions during poultry handling related to dust and bacterial endotoxin levels. Eur J Respir Dis (1984) 1.06
Non-IgE-dependent bacteria-induced histamine release from human lung and tonsillar mast cells. Clin Allergy (1987) 1.06
Endotoxin-induced inflammation and injury of the guinea pig respiratory airways cause bronchial hyporeactivity. Am Rev Respir Dis (1988) 1.02
Allergenic and biologic activity of commercial preparations of house dust extract. J Allergy Clin Immunol (1979) 0.90
Modulation of pulmonary inflammation after endotoxin inhalation with a platelet-activating factor antagonist (48740 RP). Int Arch Allergy Appl Immunol (1988) 0.87
Occupational exposures to airborne endotoxins in agriculture. Prog Clin Biol Res (1987) 0.87
TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells. Cytokine (1994) 0.85
The effect of bacterial lipopolysaccharide (LPS) on histamine release from human basophils. I. Enhancement of immunologic release by LPS. Clin Immunol Immunopathol (1985) 0.84
Histamine release from human pulmonary mast cells induced by bacterial antigens. Allergol Immunopathol (Madr) (1989) 0.82
Comparative responses of human and rabbit interleukin-1 in vivo: effect of a recombinant interleukin-1 receptor antagonist. Immunology (1992) 0.81
Investigation of the endogenous chemoattractants involved in 111In-eosinophil accumulation in passive cutaneous anaphylactic reactions in the guinea-pig. Br J Pharmacol (1994) 0.79
Endotoxin from Haemophilus influenzae enhances IgE-mediated and non-immunological histamine release. Allergy (1990) 0.78
Microorganisms and exacerbation of chronic obstructive pulmonary diseases: pathophysiological mechanisms. Allergy (1992) 0.77
Endotoxin induces eosinophil accumulation in the rat pleural cavity. Braz J Med Biol Res (1991) 0.77
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature (1981) 6.36
Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature (1973) 6.34
Calcitonin gene-related peptide is a potent vasodilator. Nature (1985) 6.13
Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet (1983) 5.64
The role of macrophages in the generation of T-helper cells. II. The genetic control of the macrophage-T-cell interaction for helper cell induction with soluble antigens. J Exp Med (1975) 5.48
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 4.42
Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med (1994) 4.36
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J Exp Med (1971) 4.03
Role of prostaglandin-mediated vasodilatation in inflammation. Nature (1977) 3.95
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science (1997) 3.70
Prostaglandin E2, prostaglandin I2 and the vascular changes of inflammation. Br J Pharmacol (1979) 3.58
Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin. J Exp Med (1972) 3.57
Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med (1983) 3.52
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35
Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol (1985) 3.18
Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature (1985) 3.11
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06
Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol (2000) 3.05
Separation of suppressor and killer T cells by surgace phenotype. Nature (1976) 3.03
Therapy of tuberculosis in mice by DNA vaccination. Nature (1999) 2.99
HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature (1987) 2.96
Different Ly antigen phenotypes of in vitro induced helper and suppressor cells. Nature (1975) 2.91
Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 2.90
Dendritic cells induce T cell proliferation to synthetic antigens under Ir gene control. J Exp Med (1980) 2.88
Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol (1996) 2.85
Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med (1995) 2.83
Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology (2005) 2.79
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Lung volume reduction surgery for emphysema. Med J Aust (1997) 2.70
Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry (2006) 2.65
T-cell lines producing antigen-specific suppressor factor. Nature (1978) 2.63
Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature (1988) 2.54
Cell interactions in the immune response in vitro. IV. Comparison of the effects of antigen-specific and allogeneic thymus-derived cell factors. J Exp Med (1972) 2.48
Tolerance, enhancement and the regulation of interactions between T cells, B cells and macrophages. Transplant Rev (1972) 2.44
Modulation of cytokine production by transforming growth factor-beta. J Immunol (1989) 2.42
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol (1985) 2.38
TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol (1992) 2.34
Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science (1985) 2.27
Role of C3 in in vitro lymphocyte cooperation. Nature (1974) 2.27
T-T interactions in the induction of suppressor and helper T cells: analysis of membrane phenotype of precursor and amplifier cells. J Exp Med (1977) 2.22
Antibody-mediated suppression of the immune response in vitro. I. Evidence for a central effect. J Exp Med (1970) 2.17
Cell-mediated immune response in vitro. II. The role of thymus and thymus-derived lymphocytes. Cell Immunol (1972) 2.15
Mediation of increased vascular permeability after complement activation. Histamine-independent action of rabbit C5a. J Exp Med (1981) 2.12
Tolerance of T-cell clones is associated with membrane antigen changes. Nature (1983) 2.10
Adhesion of a human fecal Escherichia coli strain to mouse colonic mucus. Infect Immun (1985) 2.07
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol (1988) 2.06
Suppressor cell induction in vitro. II. Cellular requirements of suppressor cell induction. Eur J Immunol (1976) 2.05
Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol (1998) 2.03
Relationship between antigen and antibody-induced suppression of immunity. Transplant Rev (1972) 2.02
Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol (1990) 2.01
Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A (1998) 2.01
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96
Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol (1998) 1.96
Cell interactions in the immune response in vitro. 3. Specific collaboration across a cell impermeable membrane. J Exp Med (1972) 1.96
Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol (1998) 1.94
Antibody-mediated suppression of the immune response in vitro. II. A new approach to the phenomenon of immunological tolerance. J Exp Med (1970) 1.93
Evidence that neutrophil accumulation induced by interleukin-1 requires both local protein biosynthesis and neutrophil CD18 antigen expression in vivo. Br J Pharmacol (1988) 1.90
Cell-mediated immune response in vitro. 3. The requirement for macrophages in cytotoxic reactions against cell-bound and subcellular alloantigens. J Exp Med (1972) 1.89
The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun (1993) 1.88
Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 1.87
Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol (1991) 1.87
Role of macrophages in in vitro induction of T-helper cells. Nature (1975) 1.84
A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol (2000) 1.84
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum (1996) 1.83
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest (1994) 1.81
The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J (2009) 1.81
Evaluation of factors affecting the membrane filter technique for testing drinking water. Appl Environ Microbiol (1982) 1.80
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum (1998) 1.79
B Cell heterogeneity - difference in the size of B lymphocytes responding to T dependent and T independent antigens. Cell Immunol (1975) 1.78
Cell interactions in the immune response in vitro. II. The requirement for macrophages in lymphoid cell collaboration. J Exp Med (1972) 1.77
Suppressor-cell induction in vitro. IV. Target of antigen-specific suppressor factor and its genetic relationships. J Exp Med (1978) 1.77
Synergy among thymocytes and peripheral lymph node cells in the in vitro generation of lymphocytes cytotoxic to alloantigens. Transplant Proc (1973) 1.76
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum (1992) 1.74
Monospecificity of bone marrow-derived lymphocytes. J Exp Med (1973) 1.74
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum (2001) 1.74
Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A (1989) 1.72
Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol (1997) 1.69
Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol (1988) 1.69
Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol (1986) 1.68
Cell-mediated immune response in vitro. I. A new in vitro system for the generation of cell-mediated cytotoxic activity. Cell Immunol (1972) 1.67
Suppressor cell induction in vitro. I. Kinetics of induction of antigen-specific suppressor cells. Eur J Immunol (1976) 1.65
Migrainous vertigo: prevalence and impact on quality of life. Neurology (2006) 1.64
LPS induces eosinophil migration via CCR3 signaling through a mechanism independent of RANTES and Eotaxin. Am J Respir Cell Mol Biol (2001) 1.64
Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev (1995) 1.63
Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today (2000) 1.62
The role of macrophages in the generation of T-helper cells. I. The requirement for macrophages in helper cell induction and characteristics of the macrophage-T cell interaction. Cell Immunol (1975) 1.62
Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol (1993) 1.62